==========
Sequence Listing was accepted.
If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).
Reviewer: Durreshwar Anjum
Timestamp: [year=2008; month=11; day=4; hr=12; min=1; sec=58; ms=426;]
==========

Validated By CRFValidator v 1.0.3

Application No: 10587529 Version No: 2.0

Input Set:

Output Set:

Started: 2008-10-08 15:32:56.516
Finished: 2008-10-08 15:32:57.817
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 301 ms
Total Warnings: 25
Total Errors: 0
No. of SeqIDs Defined: 27
Actual SeqID Count: 27

Error code		Error Description
W	213	Artificial or Unknown found in <213> in SEQ ID (1)
W	213	Artificial or Unknown found in <213> in SEQ ID (2)
W	213	Artificial or Unknown found in <213> in SEQ ID (3)
W	213	Artificial or Unknown found in <213> in SEQ ID (4)
W	213	Artificial or Unknown found in <213> in SEQ ID (5)
W	213	Artificial or Unknown found in <213> in SEQ ID (6)
W	213	Artificial or Unknown found in <213> in SEQ ID (9)
W	213	Artificial or Unknown found in <213> in SEQ ID (10)
W	213	Artificial or Unknown found in <213> in SEQ ID (11)
W	213	Artificial or Unknown found in <213> in SEQ ID (12)
W	213	Artificial or Unknown found in <213> in SEQ ID (13)
W	213	Artificial or Unknown found in <213> in SEQ ID (14)
W	213	Artificial or Unknown found in <213> in SEQ ID (15)
W	213	Artificial or Unknown found in <213> in SEQ ID (16)
W	213	Artificial or Unknown found in <213> in SEQ ID (17)
W	213	Artificial or Unknown found in <213> in SEQ ID (18)
W	213	Artificial or Unknown found in <213> in SEQ ID (19)
W	213	Artificial or Unknown found in <213> in SEQ ID (20)
W	213	Artificial or Unknown found in <213> in SEQ ID (21)
W	213	Artificial or Unknown found in <213> in SEQ ID (22)

Input Set:

Output Set:

Started: 2008-10-08 15:32:56.516
Finished: 2008-10-08 15:32:57.817
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 301 ms
Total Warnings: 25
Total Errors: 0
No. of SeqIDs Defined: 27
Actual SeqID Count: 27

Error code	Error Description
	This error has occured more than 20 times, will not be displayed

SEQUENCE LISTING

<110> Cruz, Antonio

<120> METHODS AND COMPOSITIONS USING CD3 AGONISTS

<130> 24492-020 CIP NATL

<140> 10587529
<141> 2008-10-08

<150> 10/587,259
<151> 2006-07-26

<150> PCT/CA05/00099
<151> 2005-01-25

<160> 27

<170> PatentIn version 3.5

<210> 1
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 1

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val
1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu
20 25 30

Val Lys Gly Arg Gly
35

<210> 2
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 2

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val
1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu
            20   25   30

Val Lys Gly Arg
        35

<210> 3
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MISC_FEATURE
<222> (36)..(36)
<223> wherein Arg at position 36 is attached to a NH2

<400> 3

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val
1   5   10   15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu
            20   25   30

Val Lys Gly Arg
        35

<210> 4
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 4

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1   5   10   15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
            20   25   30

<210> 5
<211> 30
<212> PRT

<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 5

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
20 25 30

<210> 6
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MISC_FEATURE
<222> (30)..(30)
<223> wherein Arg at position 30 is attached to a NH2

<400> 6

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
20 25 30

<210> 7
<211> 39
<212> PRT
<213> Heloderma horridum

<400> 7

His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> 8
<211> 39
<212> PRT
<213> Heloderma suspectum

<400> 8

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> 9
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 9

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Tyr
20 25 30

<210> 10
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 10

Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
1 5 10 15

Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser
20 25 30

<210> 11

<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> wherein Xaa at position 1 is pyroglutamate

<400> 11

Xaa Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys
1 5 10 15

Lys Gln Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met
20 25 30

<210> 12
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> wherein X at position 1 is pyroglutamate

<400> 12

Xaa Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys
1 5 10 15

Lys Gln Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Leu
20 25 30

<210> 13
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>

<221> MISC_FEATURE
<222> (1)..(1)
<223> wherein X at position 1 is pyroglutamate

<400> 13

Xaa Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp
1 5 10 15

<210> 14
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> wherein X at position 1 is pyroglutamate

<400> 14

Xaa Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Leu Asp
1 5 10 15

<210> 15
<211> 101
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 15

Met Gln Arg Leu Cys Val Tyr Val Leu Ile Phe Ala Leu Ala Leu Ala
1 5 10 15

Ala Phe Ser Glu Ala Ser Trp Lys Pro Arg Ser Gln Gln Pro Asp Ala
20 25 30

Pro Leu Gly Thr Gly Ala Asn Arg Asp Leu Glu Leu Pro Trp Leu Glu
35 40 45

Gln Gln Gly Pro Ala Ser His His Arg Arg Gln Leu Gly Pro Gln Gly
50 55 60

Pro Pro His Leu Val Ala Asp Pro Ser Lys Lys Gln Gly Pro Trp Leu

65 70 75 80

Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp Phe Gly Arg Arg Ser
85 90 95

Ala Glu Asp Glu Asn
100

<210> 16
<211> 52
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 16

Asp Leu Glu Leu Pro Trp Leu Glu Gln Gln Gly Pro Ala Ser His His
1 5 10 15

Arg Arg Gln Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro
20 25 30

Ser Lys Lys Gln Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly
35 40 45

Trp Met Asp Phe
50

<210> 17
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 17

Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp Phe
1 5 10

<210> 18
<211> 6
<212> PRT
<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 18

Tyr Gly Trp Met Asp Phe
1 5

<210> 19
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 19

Tyr Gly Trp Leu Asp Phe
1 5

<210> 20
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> wherein Xaa is either Pro or Tyr

<400> 20

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Xaa
20 25 30

<210> 21
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MISC_FEATURE

<222> (2)..(2)
<223> wherein Xaa is either Ser or Asp

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> wherein Xaa is either Gly or Phe

<400> 21

His Xaa Xaa Gly Thr Phe Ile Thr Ser Asp Leu Ser Lys Gln Met Glu
1 5 10 15

Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
20 25 30

Ser Ser Gly Ala Pro Pro Pro Ser
35 40

<210> 22
<211> 52
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 22

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys Lys Lys Ser Ser Gly Ala
35 40 45

Pro Pro Pro Ser
50

<210> 23
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 23

Tyr Gly Trp Met Asp Phe
1 5

<210> 24
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 24

Tyr Gly Trp Leu Asp Phe
1 5

<210> 25
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 25

Gly Ala Gly Ala Gly Ala Gly Ala Gly Ala
1 5 10

<210> 26
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> wherein Phe at position 4 is attached to an NH2

<400> 26

Trp Met Asp Phe
1

<210> 27
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> wherein Phe at position 4 is attached to an NH2

<400> 27

Trp Leu Asp Phe
1